Professor Claude Wischik found that the underlying pathology of Alzheimer’s known as Tau tangles is present in the brain up to 30 years before clinical symptoms develop and that the presence of this pathology is highly correlated with disease progression.

Phase 3 clinical trial begins in mild to moderate Alzheimer's Disease with a second-generation Tau Aggregation Inhibitor (TAI) aimed at halting the progression of Alzheimer's.

Phase 3 clinical trial begins in early form of dementia

US patent granted: Patent for TauRx’s next generation Tau Aggregation Inhibitor compound granted extensively